Epstein-Barr virus vaccine by 2032?
RegulamentaçãoOne-OffSaúde e medicinaChinaEuropaCrime e justiça5a
Manifold MarketsSem KYCDados de resolução verificadosRazoavelmente calibradoPrevisão da comunidade atualNão 65.3%
Previsores
5
Tipo de pergunta
binary
Metodologia
Play-money forecasting platform
Tipo de fonte
Previsão
Dados do mercado
Atualizado há 18 horas
Desatualizado26/10/25, 19:27 UTC31/12/31, 23:59 UTC
Tendências
Mercados Relacionados
Perguntas relacionadas para dar contexto, não uma comparação de contratos equivalentes.
Is Epstein-Barr virus a causative factor in multiple sclerosis?
Manifold MarketsIs the "Promethean virus" in Large Language Models real?
Manifold MarketsWill a vaccine against the Andes virus (hantavirus) be tested in humans before the end of 2027?
Manifold MarketsWill some scientist genetically engineer a virus that is virulent to anyone who isn't Han Chinese by 2038?
Manifold MarketsJeffrey Epstein confirmed to be alive before 2027?
PolymarketWill anyone be charged over Epstein disclosures?
PolymarketRegras
Resolution: YES if, by 00:00 UTC on Jan 1, 2032, at least one prophylactic EBV vaccine (an active immunization product) has received regulatory authorization for use to prevent EBV infection or EBV‑associated disease (e.g., infectious mononucleosis, post‑transplant lymphoproliferative disease) from any of the following: FDA (U.S.), EMA (EU), MHRA (U.K.), PMDA (Japan), NMPA (China), Health Canada, TGA (Australia), or if the product appears on the WHO Emergency Use Listing (EUL) or the WHO prequalification (PQ) list for EBV prevention.
- What counts:
- Prophylactic EBV vaccines intended to prevent infection and/or clinical disease (e.g., Moderna’s mRNA‑1189; ferritin‑nanoparticle vaccines; other platforms).
- Approvals may be for specific age/risk groups or limited indications (e.g., prevention of mono in adolescents, or prevention of EBV disease in transplant recipients).
- Any formal regulatory approval/authorization meeting the above criteria counts.
- What doesn’t count:
